Brevan Howard Capital Management LP Invests $305,000 in Insulet Co. (NASDAQ:PODD)

Brevan Howard Capital Management LP purchased a new stake in Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,168 shares of the medical instruments supplier's stock, valued at approximately $305,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PODD. SBI Securities Co. Ltd. bought a new position in Insulet in the fourth quarter worth approximately $36,000. Itau Unibanco Holding S.A. bought a new stake in Insulet during the 4th quarter valued at $42,000. SRS Capital Advisors Inc. raised its holdings in Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after buying an additional 56 shares during the last quarter. Friedenthal Financial bought a new position in shares of Insulet in the fourth quarter valued at $57,000. Finally, Assetmark Inc. lifted its stake in shares of Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after buying an additional 246 shares in the last quarter.

Insulet Stock Performance

Shares of PODD stock traded down $2.21 during trading hours on Tuesday, hitting $314.46. 1,469,339 shares of the company were exchanged, compared to its average volume of 714,466. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $323.00. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a fifty day simple moving average of $259.46 and a 200 day simple moving average of $264.81. The stock has a market capitalization of $22.13 billion, a price-to-earnings ratio of 54.31, a P/E/G ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.21. The company had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm's revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 EPS. Research analysts predict that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Activity at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company's stock, valued at $888,525. The trade was a 36.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.47% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

PODD has been the topic of several recent research reports. Citigroup raised their price target on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Raymond James restated an "outperform" rating and issued a $328.00 target price (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target for the company in a report on Tuesday. Canaccord Genuity Group increased their price target on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Finally, Stifel Nicolaus lifted their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average price target of $306.53.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.